Established by Asher Maroof, former R&D lead for UCB’s Bimekizumab program from its pre-clinical stages through to FDA approval, RE-AIM Therapeutics is dedicated to developing curative therapies that target disease-causing cells for patients suffering from inflammatory diseases.
Their innovative approach shows great promise in the field of autoimmunity, with the goal of offering both safe and durable clinical remission for patients.
At the BioEscalator, we are committed to creating a collaborative environment where pioneering companies like RE-AIM Therapeutics can prosper. We are excited about supporting their journey and witnessing the transformative impact of their work on the future of healthcare.
At RE-AIM, our vision is to revolutionize the treatment paradigm for patients suffering from inflammatory disease by developing novel, curative therapeutics that target disease causal cells, resetting the immune system.
Ash Maroof, CEO, RE-AIM Therapeutics